Analyst Price Target is $0.50
▲ +328.08% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for CNS Pharmaceuticals in the last 3 months. The average price target is $0.50, with a high forecast of $0.50 and a low forecast of $0.50. The average price target represents a 328.08% upside from the last price of $0.12.
Current Consensus is
Buy
The current consensus among 1 polled investment analysts is to buy stock in CNS Pharmaceuticals. This rating has held steady since July 2023, when it changed from a Hold consensus rating.
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.
Read More